Clinical trial
Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.
NCT00463268 is registered in ClinicalTrials.gov with University Hospital of Mont-Godinne as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.
- Lead sponsor
- University Hospital of Mont-Godinne
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- January 31, 2012
- Enrollment
- 83 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
osteopenia